Erratum: Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity (J Am Soc Nephrol (2017) 28 (1783–1791) DOI: 10.1681/ASN.2016060606);Megalin blockade with cilastatin suppresses drug-induced nephrotoxicity

Journal of the American Society of Nephrology

Volumn 28, Issue 6, 2017, Pages 1783-1791

  Hori, Yoshihisa ^a   Aoki, Nobumasa ^a,b   Kuwahara, Shoji ^c   Hosojima, Michihiro ^c   Kaseda, Ryohei ^b   Goto, Sawako ^b   Iida, Tomomichi ^b   De, Shankhajit ^f   Kabasawa, Hideyuki ^c   Kaneko, Reika ^b   Aoki, Hiroyuki ^c   Tanabe, Yoshinari ^d   Kagamu, Hiroshi ^e   Narita, Ichiei ^b   Kikuchi, Toshiaki ^a   Saito, Akihiko ^b  

^a Departments of Respiratory Medicine and Infectious Diseases   (United States)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^c Clinical Nutrition Science   (United States)

^d Advanced Disaster Medical and Emergency Critical Care Center and Intensive Care Units   (United States)

^e NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^f SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CILASTATIN; CISPLATIN; COLISTIN; GENTAMICIN; MEGALIN; TENOFOVIR; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG INDUCED DISEASE; EPITHELIUM CELL; GENE DELETION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; QUARTZ CRYSTAL MICROBALANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMICALLY INDUCED; KIDNEY DISEASES;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; CILASTATIN; KIDNEY DISEASES; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-2; MALE; MICE; MICE, INBRED C57BL;

EID: 85021671279     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2022010083     Document Type: Erratum

References (38)

1. Nash K, Hafeez A, Hou S: Hospital-Acquired renal insufficiency. Am J Kidney Dis 39: 930-936, 2002.
2. Venkatachalam MA, Weinberg JM, Kriz W, Bidani AK: Failed tubule recovery, AKI-CKD transition, and kidney disease progression. J Am Soc Nephrol 26: 1765-1776, 2015.
3. Talbot GH, Bradley J, Edwards JE Jr., Gilbert D, Scheld M, Bartlett JG; Antimicrobial Availability Task Force of the Infectious Diseases Society of America: Bad bugs need drugs: An update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 42: 657-668, 2006.
4. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW: Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother 54: 3717-3722, 2010.
5. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL: Colistin: The re-emerging antibiotic for multidrug-resistant Gramnegative bacterial infections. Lancet Infect Dis 6: 589-601, 2006.
6. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T, Lephart P, Kaye KS: Incidence of and risk factors for colistin-Associated nephrotoxicity in a large academic health system. Clin Infect Dis 53: 879-884, 2011.
7. Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K, Jones RN: Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 53: 4127-4132, 2009.
8. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A: High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: Efficacy and toxicity. Arch Intern Med 166: 2138-2144, 2006.
9. Pabla N, Dong Z:Cisplatin nephrotoxicity:Mechanisms andrenoprotective strategies. Kidney Int 73: 994-1007, 2008.
10. Mizuno T, Ishikawa K, Sato W, Koike T, Kushida M, Miyagawa Y, Yamada K, Hirata S, Imai E, Noda Y: The risk factors of severe acute kidney injury induced by cisplatin. Oncology 85: 364-369, 2013.
11. Saito A, Pietromonaco S, Loo AK, Farquhar MG: Complete cloning and sequencing of rat gp330/"megalin, " a distinctive member of the low density lipoprotein receptor gene family. Proc Natl Acad Sci USA 91: 9725-9729, 1994.
12. Christensen EI, Nielsen S, Moestrup SK, Borre C, Maunsbach AB, de Heer E, Ronco P, Hammond TG, Verroust P: Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. Eur J Cell Biol 66: 349-364, 1995.
13. Saito A, Sato H, Iino N, Takeda T: Molecular mechanisms of receptormediated endocytosis in the renal proximal tubular epithelium. J Biomed Biotechnol 2010: 403272, 2010.
14. Kuwahara S, Hosojima M, Kaneko R, Aoki H, Nakano D, Sasagawa T, Kabasawa H, Kaseda R, Yasukawa R, Ishikawa T, Suzuki A, Sato H, Kageyama S, Tanaka T, Kitamura N, Narita I, Komatsu M, Nishiyama A, Saito A: Megalin-mediated tubuloglomerular alterations in high-fat diet-induced kidney disease. J Am Soc Nephrol 27: 1996-2008, 2016.
15. Moestrup SK, Cui S, Vorum H, Bregengård C, Bjørn SE, Norris K, Gliemann J, Christensen EI: Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J Clin Invest 96: 1404-1413, 1995.
16. Suzuki T, Yamaguchi H, Ogura J, Kobayashi M, Yamada T, Iseki K: Megalin contributes to kidney accumulation and nephrotoxicity of colistin. Antimicrob Agents Chemother 57: 6319-6324, 2013.
17. Kahan FM, Kropp H, Sundelof JG, Birnbaum J: Thienamycin: Development of imipenen-cilastatin. J Antimicrob Chemother 12[Suppl D]: 1-35, 1983.
18. Takeda M, Narikawa S, Hosoyamada M, Cha SH, Sekine T, Endou H: Characterization of organic anion transport inhibitors using cells stably expressing human organic anion transporters. Eur J Pharmacol 419: 113-120, 2001.
19. Toyoguchi T, Takahashi S, Hosoya J, Nakagawa Y, Watanabe H: Nephrotoxicity of vancomycin and drug interaction study with cilastatin in rabbits. Antimicrob Agents Chemother 41: 1985-1990, 1997.
20. Humanes B, Lazaro A, Camano S, Moreno-Gordaliza E, Lazaro JA, Blanco-Codesido M, Lara JM, Ortiz A, Gomez-Gomez MM, Martín- Vasallo P, Tejedor A: Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats. Kidney Int 82: 652-663, 2012.
21. Nakamura T, Takano M, Yasuhara M, Inui K: In-vivo clearance study of vancomycin in rats. J Pharm Pharmacol 48: 1197-1200, 1996.
22. Jado JC, Humanes B, Lopez-Parra V, Camano S, Lara JM, Cercenado E, Tejedor A, Lázaro A: Effects of cilastatin on gentamicin-induced renal damage: In vitro and in vivo evidence.Nephrol Dial Transplant 29: iii90, 2014.
23. Orlando RA, Kerjaschki D, Kurihara H, Biemesderfer D, Farquhar MG: gp330 associates with a 44-kDa protein in the rat kidney to form the Heymann nephritis antigenic complex. Proc Natl Acad Sci U S A 89: 6698-6702, 1992.
24. Kohler JJ, Hosseini SH, Green E, Abuin A, Ludaway T, Russ R, Santoianni R, Lewis W: Tenofovir renal proximal tubular toxicity is regulated byOAT1 and MRP4 transporters. Lab Invest 91: 852-858, 2011.
25. Leheste JR, Melsen F, Wellner M, Jansen P, Schlichting U, Renner-Müller I, Andreassen TT, Wolf E, Bachmann S, Nykjaer A, Willnow TE: Hypocalcemia and osteopathy in mice with kidney-specific megalin gene defect. FASEB J 17: 247-249, 2003.
26. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K: Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration. Antimicrob Agents Chemother 47: 1766-1770, 2003.
27. Ferraro G, Massai L, Messori L, Merlino A:Cisplatin binding to human serum albumin: A structural study. Chem Commun (Camb) 51: 9436-9439, 2015.
28. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR: Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylateplatinum(II) in patients with normal and impaired renal function. Cancer Res 44: 1693-1697, 1984.
29. Hama H, Saito A, Takeda T, Tanuma A, Xie Y, Sato K, Kazama JJ, Gejyo F: Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors. Endocrinology 145: 3935-3940, 2004.
30. Kaseda R, Iino N, Hosojima M, Takeda T, Hosaka K, Kobayashi A, Yamamoto K, Suzuki A, Kasai A, Suzuki Y, Gejyo F, Saito A: Megalinmediated endocytosis of cystatin C in proximal tubule cells. Biochem Biophys Res Commun 357: 1130-1134, 2007.
31. Leheste JR, Rolinski B, Vorum H, Hilpert J, Nykjaer A, Jacobsen C, Aucouturier P, Moskaug JO, Otto A, Christensen EI, Willnow TE: Megalin knockout mice as an animal model of low molecular weight proteinuria. Am J Pathol 155: 1361-1370, 1999.
32. Tanaka-Kagawa T, Suzuki M, Naganuma A, Yamanaka N, Imura N: Strain difference in sensitivity of mice to renal toxicity of inorganic mercury. J Pharmacol Exp Ther 285: 335-341, 1998.
33. Couet W, Grégoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O: Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin Pharmacol Ther 89: 875-879, 2011.
34. Dagil R, O'Shea C, Nykjær A, Bonvin AM, Kragelund BB: Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: Insight from the nmr structure of the 10th complement type repeat domain alone and in complex with gentamicin. J Biol Chem 288: 4424-4435, 2013.
35. Mizuta K, Saito A, Watanabe T, Nagura M, Arakawa M, Shimizu F, Hoshino T: Ultrastructural localization of megalin in the rat cochlear duct. Hear Res 129: 83-91, 1999.
36. Arai M, Mizuta K, Saito A, Hashimoto Y, Iwasaki S, Watanabe T, Mineta H: Localization ofmegalin in rat vestibular dark cells and endolymphatic sac epithelial cells. Acta Otolaryngol 128: 627-633, 2008.
37. Riedemann L, Lanvers C, Deuster D, Peters U, Boos J, Jürgens H, Zehnhoff-Dinnesen A: Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Pharmacogenomics J 8: 23-28, 2008.
38. Carmellini M, Frosini F, Filipponi F, Boggi U, Mosca F: Effect of cilastatin on cyclosporine-induced acute nephrotoxicity in kidney transplant recipients. Transplantation 64: 164-166, 1997.